We utilized these compounds for in vitro assessment of SMAD2/3 following Nrp1 inhibition and activation in WT and Nrp1-KO microglial cell lines in the presence and absence of glioma associated cytokines (21). The gene discussed is SMAD2; the disease is central nervous system cancer.